Stock Price Quote

SARTHI PHARMACEUTICALS LTD.

NSE : NABSE : ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year :
Management Info
- Chairman - Managing Director
Registered Office

Address

Phone

Email

Website

Registrars Details
Listing :

NEWS

No News Found

Financials

in Millions
QTR ANNUAL
Net Profit
Gross Profit
Operating Profit
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  14600.00 (2.38%)
M.Cap ( in Cr)18295.36
RPG Life Sciences (BSE)
peergroup  2790.00 (3.84%)
M.Cap ( in Cr)4443.70
SMS Lifesciences (BSE)
peergroup  1638.00 (4.98%)
M.Cap ( in Cr)471.74
Albert David (BSE)
peergroup  1467.00 (4.98%)
M.Cap ( in Cr)797.55
Abbott India (BSE)
peergroup  28904.75 (0.22%)
M.Cap ( in Cr)61284.58

Shareholding Pattern

No Data Found

About Sarthi Pharmaceuticals Ltd.

Sarthi Pharmaceuticals Ltd. was incorporated in the year 1995. Its today's share price is 0. Its current market capitalisation stands at Rs 0 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2.58 Cr and Total Income of Rs.2.58 Cr. The company's management includes Mahesh Vijaykumar Fulpadia, Mayur Solanki, Rikesh Balkrishna Sheth, Paresh Balkrishna Sheth.

It is listed on the BSE with a BSE Code of  , NSE with an NSE Symbol of and ISIN of . It's Registered office is at 18, Sanskar Complex, Nr. Ketav Petrol Pump,Polytechnic Road,AmbawadiAhmedabad-380006, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Heda & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.